Allogeneic hematopoietic stem cell transplantation for relapsed/refractory non-Hodgkin lymphomas

Treatment of non-Hodgkin lymphomas (NHL) in children using risk-based chemotherapy protocols is currently effective in 80–95% of cases, even in advanced stages of the disease. However, relapsed/refractory forms of NHL (which are less common) have an extremely unfavorable course with low survival rates. The addition of autologous and allogeneic hematopoietic stem cell transplantation (HSCT) to a comprehensive treatment program for relapsed/refractory forms of NHL can improve treatment results due to the antitumor effect of chemotherapy drugs of the conditioning regimen and the graft-versus-tumor effect, which is, however, less significant than in leukemia. Moreover, post-transplant complications after allogeneic HSCT in some cases can offset its positive results in NHL; therefore, to reduce toxicity, especially in severe somatic status of the patient, preference is often given to reduced-intensity conditioning regimens. This article presents two clinical cases. In one case, autologous HSCT was carried out for the first relapse of Burkitt's lymphoma. However, the patient developed a second relapse and underwent allogeneic HSCT from a haploidentical donor. In the second case, HSCT from an unrelated HLA identical donor was carried out in a patient with relapsed anaplastic large cell lymphoma. Both patients received reduced-intensity conditioning regimens. This approach helped to avoid the development of severe post-transplant complications, ensuring successful engraftment and achievement of donor hematopoietic chimerism. Early after transplantation, the patient with relapsed Burkitt's lymphoma developed a second tumor – acute T-lymphoblastic leukemia, from which the patient died. Despite treatment with targeted drug crizotinib, the second patient showed lymphoma progression, which resulted in death. The patients' parents gave consent to the use of their children's data, including photographs, for research purposes and in publications.

1. Federal clinical guidelines for the diagnosis and treatment of non-Hodgkin lymphomas in children. Moscow; 2015. [Electronic resource] URL: http://nodgo.org/sites/default/files/19%20%D0%9D%D0%A5%D0%9B_%D1%80%D0%B5%D0%B4%201.pdf (access date 03.03.2024). (In Russ.).

2. Chiu B.C.-H., Hou N. Epidemiology and Etiology of Non-Hodgkin Lymphoma. Cancer Treat Res 2015; 165: 1–25. DOI: 10.1007/978-3-31913150-4_1

3. Bollard C.M., Lim M.S., Gross T.G.; COG Non-Hodgkin Lymphoma Committee. Children's Oncology Group's 2013 blueprint for research: non-Hodgkin lymphoma. Pediatr Blood Cancer 2013; 60 (6): 979–84. DOI: 10.1002/pbc.24416. Epub 2012 Dec 19. PMID: 23255391; PMCID: PMC4327936.

4. Oliveira M.C.L., Sampaio K.C., Brito A.C., Campos M.K., Murao M., Gusmão R., et al. 30 Years of Experience with Non-Hodgkin Lymphoma in Children and Adolescents: a retrospective cohort study. Rev Assoc Med Bras (1992) 2020; 66 (1): 25–30. DOI: 10.1590/1806-9282.66.1.25

5. Moleti M.L., Testi A.M., Foà R. Treatment of relapsed/refractory paediatric aggressive B-cell non-Hodgkin lymphoma. Br J Haematol 2020; 189 (5): 826–43. DOI: 10.1111/bjh.16461

6. Berning P., Schmitz N., Ngoya M., Finel H., Boumendil A., Wang F., et al. Allogeneic hematopoietic stem cell transplantation for NK/T-cell lymphoma: an international collaborative analysis. Leukemia 2023; 37 (7): 1511–20. DOI: 10.1038/s41375023-01924-x

7. Carreras E., Dufour C., Mohty M., Kröger N. (eds.). The EBMT Handbook: Hematopoietic Stem Cell Transplantation and Cellular Therapies. 7th ed. Cham (CH): Springer; 2019.

8. Peniket A.J., Ruiz de Elvira M.C., Taghipour G., Cordonnier C., Gluckman E., de Witte T., Santini G., et al. An EBMT registry matched study of allogeneic stem cell transplants for lymphoma: allogeneic transplantation is associated with a lower relapse rate but a higher procedure related mortality rate than autologous transplantation. Bone Marrow Transplant 2003; 31: 667–78. DOI: 10.1038/sj.bmt.1703891

9. Moleti M.L., Testi A.M., Foà R. Treatment of relapsed/refractory paediatric aggressive B-cell non-Hodgkin lymphoma. Br J Haematol 2020; 189 (5): 826–43. DOI: 10.1111/bjh.16461

10. Burkhardt B., Pillon M., Taj M., Garnier N., Minard V., Hazar V., et al. Role of HST in children and adolescents with refractory or relapsed NHL. Br J Haematol 2018; 182 (Suppl 1): 24 (abstract 30).

11. Satwani P., Jin Z., Martin P.L., Bhatia M., Garvin J.H., George D., et al. Sequential myeloablative autologous stem cell transplantation and reduced intensity allogeneic hematopoietic cell transplantation is safe and feasible in children, adolescents and young adults with poorrisk refractory or recurrent Hodgkin and non-Hodgkin lymphoma. Leukemia 2015; 29 (2): 448–55. DOI: 10.1038/leu.2014.194

12. Chen Y.B., Li S., Fisher D.C., Driscoll J., Del Rio C., Abramson J., et al. Phase II Trial of Tandem HighDose Chemotherapy with Autologous Stem Cell Transplantation Followed by Reduced-Intensity Allogeneic Stem Cell Transplantation for Patients with High-Risk Lymphoma. Biol Blood Marrow Transplant 2015; 21 (9): 1583–8. DOI: 10.1016/j. bbmt.2015.05.016

13. Baek D.W., Moon J.H., Lee J.H., Kang K.W., Lee H.S., Eom H.S., et al.; Korean Society of Blood and Marrow Transplantation. Real-world data of long-term survival in patients with T-cell lymphoma who underwent stem cell transplantation. Blood Cancer J 2023; 13 (1): 95. DOI: 10.1038/s41408-023-00868-w

14. Knörr F., Brugières L., Pillon M., Zimmermann M., Ruf S., Attarbaschi A. Stem Cell Transplantation and Vinblastine Monotherapy for Relapsed Pediatric Anaplastic Large Cell Lymphoma: Results of the International, Prospective ALCL-Relapse Trial. J Clin Oncol 2020; 38 (34): 3999–4009. DOI: 10.1200/jco.20.00157

15. Galimov A.N., Lepik E.E., Kozlov A.V., Gevorgian A.G., Kazantsev I.V., Yukhta T.V., et al. The treatment of relapsed/ refractory anaplastic large cell lymphoma expressing the anaplastic lymphoma kinase: a single-center experience. Pediatric Hematology/ Oncology and Immunopathology 2023; 22 (1): 22–31. (In Russ.) DOI: 10.24287/17261708-2023-22-1-22-31

16. Munakata W., Tobinai K. Thediscovery and the development of bendamustine for the treatment of non-Hodgkin lymphoma. Expert Opin Drug Discov 2016; 11 (11): 1123–30. DOI: 10.1080/17460441.2016.1233174